Risk of anemia attributable to everolimus in patients with cancer: a meta-analysis of randomized controlled trials
Background: Everolimus, an inhibitor of mammalian target of rapamycin (mTOR) used for the
treatment of various solid tumors, is associated with anemia, which can lead to morbidity and …
treatment of various solid tumors, is associated with anemia, which can lead to morbidity and …
Risk of hematologic toxicities in patients with solid tumors treated with everolimus: a systematic review and meta-analysis
T Funakoshi, A Latif, MD Galsky - Critical Reviews in Oncology/Hematology, 2013 - Elsevier
We performed a systematic review and meta-analysis of hematologic toxicities associated
with everolimus, an oral mammalian target of rapamycin (mTOR) inhibitor. Eligible studies …
with everolimus, an oral mammalian target of rapamycin (mTOR) inhibitor. Eligible studies …
Hematologic toxicities associated with mTOR inhibitors temsirolimus and everolimus in cancer patients: a systematic review and meta-analysis
J Xu, D Tian - Current medical research and opinion, 2014 - Taylor & Francis
Background: Mammalian target of rapamycin (mTOR) inhibitors, temsirolimus and
everolimus, are currently approved for the treatment of several malignancies. Hematological …
everolimus, are currently approved for the treatment of several malignancies. Hematological …
Treatment-related mortality with everolimus in cancer patients
R Wesolowski, M Abdel-Rasoul, M Lustberg… - The …, 2014 - academic.oup.com
Introduction. The overall incidence and odds of fatal adverse events (FAEs) after exposure to
everolimus are not well defined. We performed a comprehensive meta-analysis of published …
everolimus are not well defined. We performed a comprehensive meta-analysis of published …
The risk for anemia with targeted therapies for solid tumors
S Barni, M Cabiddu, P Guarneri, V Lonati… - The oncologist, 2012 - academic.oup.com
Background. Anemia is a common manifestation in patients with cancer. Little is known
about the frequency of and risk for anemia with targeted therapies used to treat solid tumors …
about the frequency of and risk for anemia with targeted therapies used to treat solid tumors …
Discontinuation of everolimus due to unrelated adverse events in cancer patients.
SC Rogers, CA Garcia, S Wu - 2016 - ascopubs.org
e14020 Background: The mTOR (mammalian target of rapamycin) inhibitor everolimus, a
targeted agent used widely in cancer patients, is often discontinued due to serious adverse …
targeted agent used widely in cancer patients, is often discontinued due to serious adverse …
[HTML][HTML] Incidence and risk of treatment-related mortality with mTOR inhibitors everolimus and temsirolimus in cancer patients: a meta-analysis
WX Qi, YJ Huang, Y Yao, Z Shen, DL Min - PloS one, 2013 - journals.plos.org
Background Two novel mammalian targets of rapamycin (mTOR) inhibitors everolimus and
temsirolimus are now approved by regulatory agencies and have been widely investigated …
temsirolimus are now approved by regulatory agencies and have been widely investigated …
Everolimus-induced hematologic changes in patients with metastatic breast cancer
A Chen, L Chen, A Al-Qaisi, E Romond, M Awasthi… - Clinical Breast …, 2015 - Elsevier
Background Everolimus, which inhibits the mammalian target of rapamycin (mTOR), is
increasingly used in breast cancer and familiarity with its full range of toxicity is critical for …
increasingly used in breast cancer and familiarity with its full range of toxicity is critical for …
Risk of fatigue and hepatic and metabolic toxicities in patients with solid tumors treated with everolimus: a meta-analysis
O Abdel-Rahman, M Fouad - Future Oncology, 2015 - Future Medicine
Background: We performed a systematic review and meta-analysis of fatigue, hepatic and
metabolic toxicities associated with everolimus intake in patients with solid tumors. Methods …
metabolic toxicities associated with everolimus intake in patients with solid tumors. Methods …
Risk of gastrointestinal and hepatic toxicities in patients with advanced breast cancer treated with everolimus: A meta-analysis of phase 3 randomized controlled trials.
e22215 Background: The introduction of everolimus (E), an mTOR inhibitor, was shown to
improve clinical benefit in endocrine and trastuzumab resistant advanced breast cancer by …
improve clinical benefit in endocrine and trastuzumab resistant advanced breast cancer by …
Related searches
- patients with cancer risk of anemia
- meta analysis risk of anemia
- patients with cancer meta analysis
- meta analysis solid tumors
- risk for anemia solid tumors
- meta analysis hematologic toxicities
- risk for anemia targeted therapies
- cancer patients everolimus pharmacokinetics
- meta analysis mtor inhibitors
- cancer patients mtor inhibitors
- cancer patients effect of hematocrit
- cancer patients hematologic toxicities
- metabolic toxicities solid tumors
- targeted therapies solid tumors
- everolimus in patients risk of anemia
- everolimus in patients meta analysis